Omeros Corporation is a biotechnology business based in the US. Omeros Corporation shares (OMER) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $11.79 – an increase of 95.52% over the previous week. Omeros Corporation employs 198 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $11.79 |
|---|---|
| 52-week range | $1.85 - $10.99 |
| 50-day moving average | $4.50 |
| 200-day moving average | $4.10 |
| Wall St. target price | $43.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-3.14 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $10.91 from 2024-11-22
| 1 week (2024-11-19) | 80.93% |
|---|---|
| 1 month (2024-10-25) | 160.38% |
| 3 months (2024-08-26) | 164.16% |
| 6 months (2024-05-24) | 225.67% |
| 1 year (2023-11-24) | 492.93% |
|---|---|
| 2 years (2022-11-25) | 405.09% |
| 3 years (2021-11-26) | 46.84% |
| 5 years (2019-11-26) | 14.33 |
| Gross profit TTM | $-71,397,000 |
|---|---|
| Return on assets TTM | -26.87% |
| Return on equity TTM | -576.33% |
| Profit margin | 0% |
| Book value | $-2.66 |
| Market Capitalization | $632.2 million |
TTM: trailing 12 months
We're not expecting Omeros Corporation to pay a dividend over the next 12 months.
Omeros Corporation's shares were split on a 1:1.96 basis on 1 October 2009 . So if you had owned 1.96 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Omeros Corporation shares – just the quantity. However, indirectly, the new 96% higher share price could have impacted the market appetite for Omeros Corporation shares which in turn could have impacted Omeros Corporation's share price.
Over the last 12 months, Omeros Corporation's shares have ranged in value from as little as $1.85 up to $10.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Omeros Corporation's is 1.476. This would suggest that Omeros Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington. .
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.